logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
Y

Y.H. Park

sungkyunkwan university(skku)
H指数:26
被引数:2,386

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases

人表皮生长因子受体2 (HER2) 阳性转移性乳腺癌脑转移患者曲妥珠单抗deruxtecan的汇总分析

ANNALS OF ONCOLOGY
IF65.4
2024-12-012
OAAI
Andre, F.; Cortes, J.; Curigliano, G.; Modi, S.; Li, W.; Park, Y. H.; Chung, W. -p.; Kim, S. -b.; Yamashita, T.; Pedrini, J. L.; Im, S. -a.; Tseng, L. -m.; Harbeck, N.; Krop, I.; Nakatani, S.; Tecson, K.; Ashfaque, S.; Egorov, A.; Hurvitz, S. A.
Analysis of Asian and non-Asian patients (pts) from the NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in pts with HR+/HER2L early breast cancer (EBC)

亚洲和非亚洲患者(pts)在NATALEE试验中，接受ribociclib(RIB)联合非甾体类芳香化酶抑制剂(NSAI)治疗人表皮生长因子受体2低表达激素受体阳性早期乳腺癌(EBC)的分析

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Xu, B.; Stroyakovskiy, D.; Sohn, J.; Park, Y. H.; Huang, C-S.; Lu, Y-S.; Jung, K. H.; Chan, A.; Zhang, J.; Lee, J.; Kim, J. H.; Chung, C-F.; Slamon, D.; Sakalosh, V.; Gao, M.; Amin, K.; Islam, S.; Im, S-A.
Capivasertib (C) plus paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial

Capivasertib (C)联合多西他赛（P）作为转移性三阴性乳腺癌（mTNBC）的一线治疗方案：CAPItello-290 III期试验

ANNALS OF ONCOLOGY
IF65.4
2024-09-012
PRE
Schmid, P.; McArthur, H. L.; Cortes, J.; Xu, B.; Cardoso, F.; Casalnuovo, M. L.; Demirci, U.; Freitas, R., Jr.; Ghosh, J.; Hegg, R.; Iwata, H.; Chuken, Y. A. Lopez; Nechaeva, M.; Robson, M. E.; Villalobos Valencia, R.; Lloyd, A.; D'Cruz, C.; Foxley, A.; Park, Y. H.
Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician's choice in HER2-low, hormone receptorepositive metastatic breast cancer in DESTINY-Breast04

DESTINY-Breast04研究中，曲妥珠单抗德鲁替康与医生选择治疗方案在HER2低表达、激素受体阳性转移性乳腺癌中的探索性生物标志物分析

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Ueno, N. T.; Niikura, N.; Yamashita, T.; Jacot, W.; Cameron, D. A.; Tsurutani, J.; Sohn, J.; Tokunaga, E.; Vidal Losada, M. J.; Park, Y. H.; Lee, K. S.; Chae, Y. S.; Prat, A.; Suto, F.; Kuwahara, Y.; Boran, A. D.; Kobayashi, M.; Kumar, V.; Aguilar, C. Orbegoso; Modi, S.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer

泛亚适应ESMO临床实践指南，用于早期乳腺癌患者的诊断，治疗和随访

ESMO OPEN
IF8.3
2024-05-011
OAAI
Park, K. H.; Loibl, S.; Sohn, J.; Park, Y. H.; Jiang, Z.; Tadjoedin, H.; Nag, S.; Saji, S.; Yusof, M. Md.; Villegas, E. M. B.; Lim, E. H.; Lu, Y. -S.; Ithimakin, S.; Tseng, L. -M.; Dejthevaporn, T.; Chen, T. W. W.; Lee, S. C.; Galvez, C.; Malwinder, S.; Kogawa, T.; Bajpai, J.; Brahma, B.; Wang, S.; Curigliano, G.; Yoshino, T.; Kim, S. B.; Pentheroudakis, G.; Im, S. A.; Andre, F.; Ahn, J. B.; Harbeck, N.
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial

曲妥珠单抗deruxtecan与曲妥珠单抗emtansine在HER2-positive转移性乳腺癌脑转移患者中的随机DESTINY-Breast03试验

ESMO OPEN
IF8.3
2024-05-0116
OAAI
Hurvitz, S. A.; Kim, S. -B.; Chung, W. -P.; Im, S. -A.; Park, Y. H.; Hegg, R.; Kim, M. -H.; Tseng, L. -M.; Petry, V.; Chung, C. -F.; Iwata, H.; Hamilton, E.; Curigliano, G.; Xu, B.; Egorov, A.; Liu, Y.; Cathcart, J.; Bako, E.; Tecson, K.; Verma, S.; Cortes, J.
Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01)

曲妥珠单抗deruxtecan在先前治疗的HER2-positive转移性乳腺癌患者中的应用: 一项II期临床试验 (DESTINY-Breast01) 的最新生存结果

ANNALS OF ONCOLOGY
IF65.4
2024-03-0118
OA
Saura, C.; Modi, S.; Krop, I.; Park, Y. H.; Kim, S. -B.; Tamura, K.; Iwata, H.; Tsurutani, J.; Sohn, J.; Mathias, E.; Liu, Y.; Cathcart, J.; Singh, J.; Yamashita, T.
Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis
ANNALS OF ONCOLOGY
IF65.4
2023-11-010
PRE
Park, Y. H.; Im, S-A.; Ahn, J-H.; Kim, M. H.; Cortes, J.; Dent, R. A.; Pusztai, L.; McArthur, H. L.; Kummel, S.; Denkert, C.; O'Shaughnessy, J.; Mouret-Reynier, M-A.; Ferreira, M. I. R.; Cortes, M. Gion; Boileau, J-F.; Hui, R.; Zhu, Y.; Pan, W.; Karantza, V. V.; Schmid, P.
Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study
ANNALS OF ONCOLOGY
IF65.4
2023-10-0114
PRE
Modi, S.; Jacot, W.; Iwata, H.; Park, Y. H.; Vidal Losada, M. J.; Li, W.; Tsurutani, J.; Zaman, K.; Ueno, N. T.; Prat, A.; Papazisis, K.; Rugo, H. S.; Harbeck, N.; Im, S-A.; De Laurentiis, M.; Orbegoso, C. M. A.; Yung, L.; Cheng, F-C.; Cheng, Y.; Cameron, D. A.
KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy (chemo), followed by adjuvant pembro or pbo plus endocrine therapy (ET) for early-stage high-risk ER+/HER2e breast cancer
ANNALS OF ONCOLOGY
IF65.4
2023-10-0153
PRE
Cardoso, F.; McArthur, H. L.; Schmid, P.; Cortes, J.; Harbeck, N.; Telli, M. L.; Cescon, D. W.; O'Shaughnessy, J.; Fasching, P.; Shao, Z.; Loirat, D.; Park, Y. H.; Fernandez, M. E. Gonzalez; Liu, Z.; Yasojima, H.; Ding, Y.; Jia, L.; Karantza, V. V.; Tryfonidis, K. E.; Bardia, A.

研究方向

暂未获取到该数据
J
Javier Cortés
H 指数:113论文数:1,481被引数:6.9万
N
Nadia Harbeck
H 指数:131论文数:2,063被引数:8.6万
R
Rebecca Dent
H 指数:58论文数:320被引数:2.2万
S
S-A. Im
H 指数:21论文数:181被引数:1,857
J
Joohyuk Sohn
H 指数:59论文数:635被引数:2.7万
F
Fátima Cardoso
H 指数:103论文数:824被引数:6.5万
H
Heather L. McArthur
H 指数:43论文数:310被引数:1.0万
P
Peter Schmid
H 指数:61论文数:509被引数:2.4万
P
Peter A. Fasching
H 指数:121论文数:2,055被引数:7.9万
L
LiuMark
H 指数:114论文数:1,398被引数:6.8万